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Abstract: Surgical management of glaucoma offers a means of effective disease control.
A gel stent that facilitates drainage to the subconjunctival space offers intraocular pressure (IOP)
reduction similar to traditional glaucoma filtering surgeries in a less invasive manner. However,
like all subconjunctival filtering procedures that result in a bleb, fibrosis can present as a cause of
elevated IOP. The following proposed techniques and recommendations for managing elevated
IOP due to bleb fibrosis after gel stent implantation are based on the clinical experience of the
authors. The goal of this paper is to improve outcomes following gel stent surgery by providing
guidance on assessment of bleb function and strategies for bleb enhancement.
Keywords: glaucoma gel stent, bleb management, bleb fibrosis, glaucoma surgery, glaucoma
filtering surgery, bleb needling

Introduction
The glaucoma treatment landscape has changed significantly in the last few years
with the introduction of a variety of new surgical procedures. While the use of the
subconjunctival space to drain aqueous humor from the anterior chamber has been a
cornerstone of glaucoma surgery for more than a century,1 traditional bleb-forming
procedures, such as trabeculectomy, are associated with significant risks. The XEN
gel stent (Allergan PLC, Irvine, CA, USA) seeks to achieve outcomes similar to a
trabeculectomy with higher predictability, faster recovery, less tissue manipulation,
and fewer sight-threatening complications.2,3
The gel stent is a hydrophilic tube 6 mm long with an inner diameter of ~45 µm
that drains aqueous from the anterior chamber to the subconjunctival space. The device
is implanted ab interno to minimize tissue disruption and is designed to restrict the
flow of aqueous in order to minimize the risk of hypotony.4 General recommendation
for preoperative assessment, surgical technique, and postoperative follow-up has been
published.5 However, very few guidelines on management options for bleb failure
are available.

Wound healing
Correspondence: Arsham Sheybani
Department of Ophthalmology and Visual
Sciences, Washington University School
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The natural wound healing process after filtration surgery may result in decreased
aqueous outflow due to subconjunctival and episcleral fibrosis. Furthermore, the mere
presence of fluid or a pressure head in the subconjunctival space stimulates a cellular
reaction that reduces tissue porosity.6 The aqueous in glaucoma patients and others
with elevated IOP contains higher levels of inflammatory cytokines PGE2 and TGFβ,
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substances that play a key role in inflammation and postoperative fibrosis.7,8 As inflammation and fibrosis have been
primary causes of failure in filtering surgeries,9 understanding
the wound healing process is advantageous to preventing
filtration failure. The first stage of wound healing is the
inflammatory phase, of which hemostasis is an integral part.
Blood clotting results in the secretion of pro-inflammatory
and proangiogenic cytokines, thereby impacting the diameter
and permeability of the conjunctival and episcleral vessels.
In addition, the trauma of the procedure induces the release
of macrophage-recruiting chemotoxins that further stimulate
the secretion of growth factors. Fibroblasts proliferate and
subsequently deposit type 3 collagen. During the maturation
phase, balanced production and degradation of the extracellular matrix accompanied by the production of type 1 collagen produce a tissue-strengthening effect.10 These collagen
deposits can limit filtration.
In bleb development, the remodeling process is continuous, and subconjunctival fibrotic tissue can form early or
late after surgery. Clinically, this tissue reaction can result
in an encapsulated or a fibrotic bleb. If the bleb becomes
encapsulated by tissue, it usually presents as a tense, elevated,
smooth dome with a thick wall and an aqueous-filled cavity.
In this situation, the surface area involved in filtration is limited which may lead to elevated IOP despite the presence of
the bleb. Encapsulated blebs typically form between 2 and
6 weeks following traditional filtration surgery and occur in
8.3%–28% of eyes filtered.11
Subconjunctival fibrosis usually appears clinically as a
flat bleb and is due to a more aggressive cicatrizing response.
This can occur postoperatively at any time, although it typically happens in the first few months after surgery. The bleb
created by a gel stent has some similarities to trabeculectomy
blebs, although there are also significant differences. The
authors of this paper present management strategies specific
to gel stent blebs.

Bleb failure risk factors
Increased risk of bleb failure is associated with the following factors: young age, aphakia, active anterior segment
neovascularization, conjunctival inflammation, uveitis,
chronic medication use, previously failed glaucoma filtering
surgery, and race, among others. The use of topical prostaglandins and beta blockers, the most common first-line
treatments for glaucoma, has also been shown to increase
the recruitment of inflammatory cells and intensify the
wound healing cycle.12,13
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Preoperative conjunctival optimization
During the preoperative period, it is beneficial to eliminate or
reduce causes of conjunctival inflammation.14 This involves
treating ocular surface and lid margin diseases as well as
reducing toxicity to the conjunctiva from chronic glaucoma
medication use. This is generally achieved by administering
topical steroids, reducing or stopping topical IOP-lowering
medications (replacing them with preservative-free [PF]
alternatives and/or oral acetazolamide), and using PF lubricants, cyclosporine, or other interventions.5 Depending upon
the severity of the case, any combination of the above can
be implemented 1–4 weeks prior to surgery.

Intraoperative optimization
Intraoperative factors can also be optimized to reduce the
risk of fibrosis.5 It is important to ensure that the distal tip
of the implant is free and mobile (not caught within tenons
tissue). This facilitates the formation of a diffuse, unrestricted
bleb. The implant should be positioned ~1 mm in the anterior chamber, 2 mm in the scleral channel, and 3 mm in the
subconjunctival space to ensure outflow occurs as posterior
to the limbus as possible. This positioning will also help to
prevent migration of the implant.5
Pharmacologic agents to modulate the wound healing
response can also be used at the time of surgery. Differences
in age, ethnicity, and prior surgical outcomes among patients
dictate the need for tailoring of the antifibrotic strategy to
suit the needs of the individual patient.
The use of antimetabolites intraoperatively and postoperatively in subconjunctival filtering surgeries has been
reported.15,16 Antimetabolites such as mitomycin C (MMC)
and 5-fluorouracil (5-FU) have both been successfully used
to reduce the scarring process.17,18 MMC is an alkylating
agent that interferes with the cell cycle and induces apoptosis
of fibroblasts.19 5-FU is an antimetabolite that specifically
antagonizes various phases of protein synthesis.20 In traditional filtration surgery, MMC has been found to be more
effective than 5-FU.21 However, oxidized MMC is inactive
and requires chemical or enzymatic reductive activation to
bind to DNA, after which it inhibits DNA replication, mitosis,
and protein synthesis.22,23 For those cases where MMC does
not appear to have any effect, this is possibly due to a lack
of chemical or enzymatic activation. In these instances, the
use of 5-FU is recommended.
It should be noted that in early studies of the first generation of the XEN gel stent, no MMC or other antifibrotic agent
was used, and the failure rate was between 50% and 80%.24,25
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Failure rates were reduced when MMC was utilized. There
is growing evidence that injecting MMC at the time of XEN
implantation and also during needling procedures is becoming the standard of care.25–27 As an alternative, the use of
5-FU during needling procedures has also been shown to
be useful.28
Finally, better control of intraoperative bleeding can help
reduce the secretion of proinflammatory and proangiogenic
cytokines, improve visibility, and minimize the wound healing response. Using topical phenylephrine may help with
vasoconstriction and avoiding subconjunctival and scleral
vessels may help reduce subconjunctival hemorrhage.

Postoperative wound modulation
Corticosteroids have been traditionally used to stunt fibrosis by modifying the inflammatory response following
glaucoma-filtering surgery, and their use appears to correlate
with better IOP control.29–32 Although glaucoma patients are
at heightened risk for a steroid response,33 steroid response
is less common after filtering surgery.
Prophylactic injections of 0.1 mL of 5-FU (50 mg/mL) to
the bleb area can be performed during the early postoperative
period at the slit lamp and have been reported to reduce
the possibility of more invasive interventions following
trabeculectomy.34 Some authors recommend doing this
routinely at week 2 or 3, without waiting for the bleb morphology to change or the IOP to rise. However, the authors
suggest avoiding prophylactic use of 5-FU in cases where
IOP is #8 mmHg or in presence of prominent blebs.
Vascular endothelial growth factor (VEGF) plays a role
in physiological and pathological angiogenesis, and higher
levels of VEGF are associated with failed glaucoma filtering
surgeries.35 Therefore, injections of anti-VEGF agents bevacizumab and ranibizumab have also been used to modulate
wound healing. In general, the use of anti-VEGF agents is
associated with more diffuse blebs with reduced vascularity
and reduced needling rates.36 However, the use of anti-VEGF
does not appear to produce a lower IOP when compared to
the use of MMC.37–39 Overall, anti-VEGF agents have some
advantages and may be complementary to MMC,40 but have
yet to establish better results over other antiscarring options
currently available.

Enhancement after implant placement
The XEN stent is currently the only ab interno micro-invasive
glaucoma surgery (MIGS) capable of being enhanced by
needling in the postoperative phase. This is in stark contrast
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to the majority of MIGS in which medications are the only
option when IOPs are not at goal. Needling is a secondary
procedure intended to free restrictions to aqueous outflow
due to fibrosis, and it has been shown as an effective way to
re-establish aqueous flow and lower IOP.41,42 The Preferred
Practice Patterns published by the American Academy of
Ophthalmology also include needling as an effective means
of reviving filtering blebs.43
Bleb appearance and IOP should be factored in the
decision-making process when considering needling a
XEN bleb. A high bleb with a hyporeflective wall has
been described as characteristic of a well-functioning trabeculectomy bleb.44 In contrast, a bleb following gel stent
placement is rather low-lying and diffuse,45–47 and slit lamp
assessment of improper outflow due to increasing tissue
resistance can be initially challenging. Therefore, IOP is the
best parameter to evaluate the need to release fibrosis during
the surgeons’ learning curve, rather than the bleb appearance. The ideal IOP on postoperative day 1 is between 3 and
10 mmHg.5 If the IOP is in the high teens or above in the
early postoperative period, this may represent an implant
that is imbedded in tenons tissue and surgeons should consider needling (Figure 1).26
When the IOP is elevated, the surgeon should first perform gonioscopy to confirm the positioning of the stent,

Figure 1 Left eye showing a curved implant (caught in tenon) that is visible under
conjunctiva after stent implantation. IOP is 20 mmHg on four medications (IOP
21 mmHg after DOC at slit lamp). This is a good candidate to perform needling.
Courtesy of Vanessa Vera, MD.
Abbreviations: IOP, intraocular pressure; DOC, digital ocular compression.
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Table 1 Factors to consider in XEN bleb intervention
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Step 1: Measure the intraocular pressure (IOP)

Weaker

Stronger

IOP

Is IOP elevated (irrespective of bleb appearance)?

No

Yes

IOP vs target

Is IOP at/below target or above target?

At/below target IOP

Above target IOP

Change over time

Is IOP stable or has it increased since last followup?

Stable

Increased

Step 2: Rule out other causes
Steroid response

Is the patient using steroid medications?

Yes (consider steroid
response if bleb is present)

No

Occlusion of the XEN
internal ostium

Is the anterior chamber end of the implant
occluded? (gonioscopy)

Yes (consider other rescue
strategies)

No

Step 3: Assess the bleb and implant
Bleb appearance
(slit lamp or optical
coherence tomography)

Is the bleb elevated? Are microcysts present?

Elevated bleb with microcysts
present

Low, thick bleb without
microcysts present

Response to digital
ocular compression
(DOC)

Is it possible to increase the size of the bleb
following DOC? If so, how easily and to what
extent?

Bleb size increase over a large
area in response to modest
DOC

No bleb size increase in response
to considerable DOC

Mobility of implant

Is the tip of the implant still mobile
(independently of the conjunctival tissue)?

Implant freely mobile
independently of the
surrounding conjunctiva

Implant fixed within conjunctival/
tenon tissue (Figure 1)

Mobility of the
conjunctiva

Is the conjunctiva and tenon tissue mobile and
adjacent to the implant?

Tissues are mobile

Tissues are immobile

Bleb patency assessment
(BPA)

How easily can the contents of the bleb be
moved posteriorly (using a blunt instrument or
finger pressure on the eye lid)?

Bleb contents can be easily
dispersed posteriorly

Bleb contents cannot easily enter
surrounding tissue

Visibility of the implant

Is the implant visible beneath the conjunctival
tissue?

Implant obscured by opaque
overlying tissues – consider
revision (Figure 2)

Visible implant (Figure 1)

ensure that it is patent at both ends, verify that the internal
ostium is not occluded, and rule out retained viscoelastic.
It is also worthwhile to explore if the patient is manifesting an elevated IOP response to the postoperative steroid
regimen. In rare cases, YAG laser and/or iridoplasty may
be performed through a gonioscopy mirror to remove an
internal ostium obstruction such as pigment, Descemet’s
membrane, iris, blood, etc. Table 1 lists the factors to
consider and their influence on the decision to needle the
XEN bleb.

Timing and technique of needling
The optimal time to perform a needling procedure after the
XEN gel stent surgery is not well elucidated. In general, needling occurs in the first 2–3 months after surgery. However,
if the IOP is not at goal and the bleb area is contracting, bleb
needling should be considered when the stent can be visualized under the conjunctiva. If and when needling occurs, the
authors describe three different types of needling:
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· Type 1: dissection of fibrosis in the subconjunctivalintratenon space
· Type 2: clearance of a fibrotic cap at the external
implant tip
· Type 3: needling of an encapsulated bleb if aqueous suppressant therapy proved unsuccessful (or if preferred, as
first approach).
Many surgeons find it useful to use a bent needle/blade as
the angle aids access to the desired site and facilitates rotating
the cutting edge of the tool. A 27-gauge needle is useful for
mechanically increasing the bleb area. A 30-gauge needle is
preferred for fine needling when there is no scarring present
and the surgeon wants to clear the implant tip. Many surgeons
also find a 23/24-gauge microvitreoretinal blade particularly
efficacious as the fine cutting edge can cut away denser scars
and clear the delicate tip of the stent.
As this paper is a presentation of the authors’ considerable experience, they find it helpful to share their individual
needling techniques.
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Arsham Sheybani, MD
I perform needling at the slit lamp with tetracaine or lidocaine
hydrochloride ophthalmic gel as a topical anesthesia. It is
important to avoid subconjunctival hemorrhage, and therefore I place a drop of phenylephrine prior to the procedure
to blanch the vessels. Pressing a tetracaine-soaked cotton tip
over the area of needling also eliminates pain for the patient.
Holding the eye open with a lid speculum is not required but
may be used at the surgeon’s discretion. I generally use my
third digit to elevate the lid while my index finger and thumb
hold the needle. Insert a 27-gauge needle 2–3 clock hours
away from the XEN gel stent site and once the needle reaches
the implant, gently sweep it above and below the distal end
of the stent to clear the fibrous attachments. I consider the
procedure successful if the bleb has a very low elevation and
the implant is mobile.
If there is no flow of aqueous visible, I may intentionally
amputate the tip of the stent with my needle. The rational is
that the implant tip is imbedded in tenons tissue and freeing it
will allow aqueous to flow. I have also performed YAG laser
to the internal portion of the XEN if the bleb is not raised after
needling. If there is no ischemia in the conjunctiva after the
original XEN implantation, follow needling with an injection
of 20–40 µg of MMC around the bleb area and/or 0.1 mL of
5-FU for a total of 5 mg behind the bleb.
I direct the patient to stop use of any topical glaucoma
medications and prescribe prednisolone acetate and an antibiotic for 1 week. I will usually try needling the bleb twice.
If needling fails twice but I know there is flow through the
implant, I will perform an open revision. If I cannot detect
flow through the implant, I will proceed with a tube shunt.
In a few instances, I have performed a second XEN implant.
Video 1 XEN needling by Arsham Sheybani.

Iqbal Ike K Ahmed, MD
Prior to needling, I first evaluate the conjunctiva to make
sure it is healthy. If the conjunctiva is very inflammed,
I delay needling, cease any agents that may be causing
inflammation, prescribe a topical corticosteroid, and treat
any blepharitis.
The day of the needling, I prepare the eye with tetracaine,
iodopovidone, antibiotics, etc. In patients where 0.4 mg/mL ×
0.1 mL of MMC (40 µg absolute dose) was used at the
time of surgery, I begin the needling procedure by injecting
0.5 mg/mL × 0.15 mL of MMC (75 µg absolute dose) into
the subconjunctiva making sure it covers the distal end of
the stent. I do not mix it with lidocaine. I use 5-FU if the
MMC does not seem to be having the desired effect. I may
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use an anti-VEGF agent if the eye is very red at the time of
needling and repeat later as needed.
At the slit lamp, I use a 27-gauge slit knife (MANI, Inc.,
Tochigi, Japan) bent to make it short, and enter the conjunctiva
in the adjacent quadrant. I find a lid speculum gets in my way,
so I ask the patient to look down. I slide the knife under the
distal end of the stent, swipe it toward the fornix, and then
repeat the action above the stent. I repeat this motion as needed
to release fibrosis and allow the XEN gel stent to be positioned
more anteriorly and superficially. If necessary, I will amputate
the distal end of the stent. I expect to see the stent free and
mobile, the bleb raising, and the fibrotic tissue swept away. I
will inject sodium hyaluronate once I have a bleb.
A surgeon could perform the procedure in the operating
room initially if uncertain at the slit lamp. I recommend
needling a bleb when IOP is elevated and the bleb starts
contracting, but before the bleb is gone; do not miss the
opportunity. It is important to know which cases should go
straight to open revision (Figure 2). I will attempt needling
twice before moving on to another therapeutic option.
Video 2 Xen needling by Iqbal Ike K Ahmed.

Ingeborg Stalmans, MD
If the conjunctiva is hypervascular, I use subconjunctival
injections of bevacizumab, topical corticosteroids, and
preservative-free glaucoma drops days or weeks prior to
needling. I mostly perform needling in the operating room.
On needling day, I prepare the eye by alternating 3 drops
of tetracaine, with 2 drops of apraclonidine as a vasoconstrictor, and then iodopovidone. My technique for clearing fibrosis
depends on the type of blockage present. For a clearly visible
stent without obvious scar, I use a 30-gauge needle. I first
aim for the tip to see if pulling sub-Tenons away will resume
aqueous outflow. If not, I very cautiously swipe over and
under the stent, approaching the stent very closely to open
up the “sock” around it. The stent can very easily be cut, so
it is important to use caution.
If the stent tip is free and mobile and slow bleb formation
is visible, I am satisfied with the needling. Often, I will digitally massage the eye to convincingly see the bleb formation.
Sometimes, it is possible to see sub-Tenon’s capsule being
displaced posteriorly.
Video 3 Needling fibrotic bleb after XEN + subconjunctival injection of anti-fibrotics.
If there is a scar around or behind the stent, I use a
27-gauge vitreoretinal blade to cut through the scar to create a new filtering space. For a thick-walled, encapsulated
bleb that has not responded to topical aqueous suppressants,

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

689

Dovepress

Clinical Ophthalmology downloaded from https://www.dovepress.com/ by 128.252.174.220 on 16-Aug-2019
For personal use only.

Vera et al

Figure 2 Photograph A (left) shows the implant visible in the anterior chamber (blue arrow). Photograph B (right) shows the implant visible with difficulty (blue oval) under
the conjunctiva, IOP of 20 mmHg on three medications. This is a poor candidate for needling. Courtesy of Vanessa Vera, MD.
Abbreviation: IOP, intraocular pressure.

I use a 27-gauge vitreoretinal blade to gently cut the wall of
the cyst open.
Video 4 Needling an encapsulated bleb after XEN
gel stent.
After needling, I first inject 0.05 mL of bevacizumab at
25 mg/mL (total dose 1.25 mg) into the subconjunctiva just
behind the tip of the stent, followed by 0.1 mL of MMC at
0.1 mg/mL (total dose 10 µg) posterior to that. My objective
is to keep the MMC away from the limbus and have the complementary effect of the two antiscarring agents. I also inject
a subconjunctival steroid depot inferiorly. Postoperatively,
I have the patient use a topical antibiotic four times a day
for a few weeks and a topical corticosteroid six times a day
for 1 month and then slowly taper.
I recommend needling only when the stent is visible, and
to use meticulous preparation to avoid bleeding. I will generally perform needling just once, and will perform it twice
only in exceptional cases. I prefer bleb revision if there is
thick scar, or inserting a second XEN gel stent if there is no
visible scar. Lack of scarring indicates that the first implant
was likely not well placed or not patent. Otherwise, I will
move on to another filtering surgery.

Dan Lindfield, MD
I personally use two approaches to postoperative bleb
management: pharmacological bleb modulation with 5-FU
and/or physical bleb modulation with needling.
I perform pharmacological bleb modulation in all of my
patients prophylactically. Three weeks after XEN implantation, I inject 0.1 mL of 50 mg/mL solution of 5-FU (5 mg)
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into the subconjunctiva above the XEN gel stent distal tip.
I only withhold this step if IOP is #8 mmHg or over draining.
When pharmacological bleb modulation fails, I perform
physical bleb modulation or needling in the operating room.
I apply topical adrenaline (1 mg in 1.0 mL) on a cotton swab
to blanch the area. In cases of primary needling, I use a
30-gauge long needle to inject 0.1 mL of 5-FU (50 mg/mL);
in the rare cases that I perform needling a second time,
I switch to 0.1 mL of 0.2 mg/mL MMC.
I enter the conjunctiva as far away from the stent tip as possible to minimize potential entry site leak. If the bleb deflates
through the entry site, it is less likely to function. I then perform
copious sweeping while trying to avoid hemorrhage. I expect
to see a slow filling of the bleb area. I suggest new surgeons
use topical adrenaline and perform needling in the operating
theater as you will have more control and a better view of the
implant. Avoid any conjunctival vessels in addition to taking
care not to perforate the gel stent.

Vanessa Vera, MD
If I suspect I might need to perform needling, (IOP starts
creeping up, bleb starts shrinking, conjunctival vascularity is excessive, etc), I start preparing the conjunctiva
by increasing topical corticosteroids and/or injecting a
subconjunctival anti-VEGF if vascularity is a concern.
On the day of the needling, if the conjunctiva is vascular,
I use 20–40 µg of MMC, injected 10 minutes prior to the
needling procedure. If the conjunctiva is avascular, I prefer
to inject 0.1 mL (50 mg/mL) of 5-FU (5 mg) into the bleb
area after needling is performed.
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Figure 3 Photograph A (right) showing flat bleb and implant (blue oval) under the conjunctiva before needling procedure. Photograph B (left) showing bleb restored with
mild subconjunctival hemorrhage, air bubbles, and implant (blue oval) after needling procedure. Courtesy of Vanessa Vera, MD.

I perform needling at the slit lamp using a 27-gauge
bent needle on an insulin syringe. I ask the patient to look
down and enter the conjunctiva 2–3 clock hours away from
the implant. I place my needle bevel halfway under the subconjunctival portion of the implant, not too close to scleral
exit as it is easy to accidentally cut it, nor at the implant tip.
I then sweep away from the implant. I go back again, this time
placing the needle bevel halfway over the stent, and sweep
away. If I do not see any bleb formation I repeat this, focusing on the area where most resistance was felt. I continue to
sweep with the needle until the fibrotic tissue is mechanically broken and satisfactory outflow is seen. Ideally, at the
end of the procedure I will see that the tip of the implant is
free and mobile from the surrounding tissue and that there
is low elevation of the conjunctiva. This low elevation can
make the implant a bit more difficult to visualize compared
to the pre-needling view (Figure 3). Following the procedure,
I use the same antibiotic and steroid regimen as after the
initial surgery.
I avoid entering with the needle in an area that is avascular
or too close to where the bleb will form. I also avoid subconjunctival hemorrhage, perforating the conjunctiva and/or
inadvertently cutting the implant (Figure 4). I do amputate
the distal end of the stent when there is no flow. To do this,
I place the needle bevel angled over the implant and press
down against the sclera. I will attempt needing twice, but
if the bleb fails within a few days of first needling or if too

Clinical Ophthalmology 2019:13

much tissue resistance was felt during first needling, then I
will not needle a second time.
I recommend performing needling only when the stent
is plainly visible under the conjunctiva, without the aid
of a laser suture lysis lens or a gonio lens to locate it. If
you cannot see the stent, then that is not the right patient
to needle.

Figure 4 Photograph showing inadvertent cut of a gel stent implant (blue arrow)
after failed needling procedure. Courtesy of Vanessa Vera, MD.
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Figure 5 Photograph A (left) shows a stent visible under conjunctiva. IOP was 24 mmHg on two medications after gel stent implantation. Subconjunctival injection of 20 µg of
MMC + needling was performed on slit lamp during that visit (IOP was 8 mmHg right after needling + digital ocular compression). Photograph B (right) shows a bleb present
with avascular conjunctiva (6 months after needling). IOP was 10 mmHg on no medication. Courtesy of Vanessa Vera, MD.
Abbreviations: IOP, intraocular pressure; MMC, mitomycin C.

There is consensus among all authors that the goal is
to have the XEN gel stent released from Tenon’s capsule,
the distal end free and mobile, and a low, diffuse bleb. Needling should not be performed more than twice, and should
not be attempted at all if the implant is not clearly visible.
Achieving an IOP #10 mmHg right after needling (Figure 5)
may be indicative of good long-term prognosis.5
Just as with the initial surgical procedure, the potential
risks following needling of the XEN bleb are minimized
compared to needling a trabeculectomy bleb.28 While profound hypotony, flat chamber, and hyphema are all possible complications after needling a trabeculectomy bleb,
they are all very unlikely to happen following needling of
a XEN bleb.

Bleb revision with open conjunctiva
In cases when the implant cannot be visualized under the
conjunctiva or with poorly functioning encapsulated bleb,
a bleb revision may be the most appropriate next step. The
conjunctiva is incised and opened at the limbus spanning
2–3 clock hours. The posterior conjunctiva is then dissected
down to the scleral bed and all adhesions that have formed
between the conjunctiva and the sclera are released. Gentle

Alternative options to needling
While needling can be very effective, it is not always successful at achieving the desired IOP. When needling has
been attempted and an acceptable IOP is not achieved and
sustained, or in cases where the XEN gel stent cannot be
visualized under the conjunctiva due to a dense and opaque
layer of tissue, other options should be considered. These
may include:
· Resume IOP-lowering medications. If needling was
recently performed, consider starting with a preservativefree aqueous suppressant5 instead of a prostaglandin to
avoid adding proinflammatory factors (Figure 6).
· Perform a bleb revision (open conjunctiva).
· Consider converting to a different surgical treatment.
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Figure 6 Image showing right eye 6 weeks after XEN gel stent implantation with
an IOP of 21 mmHg on no medications (preoperatively, IOP was 20 mmHg on
three medications). The implant is barely visible under the conjunctiva (blue oval).
The patient is a poor candidate for needling, so the decision was made to resume
glaucoma medications. At follow-up 26 months after XEN gel stent implantation,
IOP was 15 mmHg on three medications. Courtesy of Vanessa Vera, MD.
Abbreviation: IOP, intraocular pressure.
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cautery is performed to maintain hemostasis. The dissection
should be performed with caution when approaching the area
of stent placement through the sclera. Once the implant is
fully released from the fibrotic tissue, ensure the implant is
patent and flowing by injecting balanced salt solution (BSS)
into the anterior chamber (Video 5). Outflow through the
implant is difficult to visualize as the flow rate may be very
low; therefore, fluorescein strips may be used along with
sponges to determine the absence or presence of flow.
Video 5 Bleb revision by Iqbal Ike K Ahmed.
After the stent is fully liberated and flow is confirmed,
it may still be necessary to perform additional dissection to
remove adhesions and create a potential space for filtration.
In some cases, a tenectomy may be necessary to prevent
future implant fibrosis. The conjunctiva may be closed with
sutures to ensure a watertight seal. The authors recommend
an injection of an antifibrotic agent during bleb revision
surgery (MMC, 5FU, anti-VEGF, and/or corticosteroids).

Conclusion
The key to successful needling include identifying the right
candidate for intervention and using the appropriate technique.
Except in cases of encapsulation when aqueous suppressants
have proven unsuccessful, needling should not be attempted in
cases where the XEN gel stent is not visible under the conjunctiva. If the stent cannot be visualized, surgeons should consider
a bleb revision or other interventions, such as restarting topical
medications or another glaucoma procedure.
If the patient is an appropriate candidate for needling,
reducing conjunctival inflammation or subconjunctival
hemorrhage can help improve the chances for success.
An inflamed conjunctiva should be treated pre-emptively.
The use of antimetabolites and other antifibrotic agents
are associated with greater needling success rates, and the
authors encourage their use. Freeing the XEN implant from
Tenon’s tissue and elevating a bleb is the goal of needling.
After needling, there should be a reduction in IOP confirming improved outflow.
The suggested approaches to bleb management following
implantation of the XEN gel stent are based on published
best practices in ophthalmology and the collective, considerable experience of the authors. This information is meant to
complement, not replace formal training with the XEN gel
stent, and should always be applied to an individual patient
at the surgeon’s discretion.
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